Page 2059 - Williams Hematology ( PDFDrive )

2034 Part XII: Hemostasis and Thrombosis <CN>: <ct> PB

79. Selleng S, Schreier N, Wollert HG, Greinacher A: The diagnostic value of the anti-PF4/ 106. Magnani HN, Gallus A: Heparin-induced thrombocytopenia (HIT). A report of 1,478
heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-
Anesth Analg 112:774, 2011. 2004. Thromb Haemost 95:967, 2006.
80. Sachs UJ, von Hesberg J, Santoso S, et al: Evaluation of a new nanoparticle-based lateral- 107. Blackmer AB, Oertel MD, Valgus JM: Fondaparinux and the management of heparin-
flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). induced thrombocytopenia: The journey continues. Ann Pharmacother 43:1636, 2009.
Thromb Haemost 106:1197, 2011. 108. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I: Fondaparinux for the treatment
81. Meyer O, Salama A, Pittet N, Schwind P: Rapid detection of heparin-induced platelet of acute heparin-induced thrombocytopenia: A single-center experience. Clin Appl
antibodies with particle gel immunoassay (ID-HPF4). Lancet 354:1525, 1999. Thromb Hemost 16:663, 2010.
82. Leroux D, Hezard N, Lebreton A, et al: Prospective evaluation of a rapid nanoparticle- 109. Warkentin TE, Pai M, Sheppard JI, et al: Fondaparinux treatment of acute heparin-
based lateral flow immunoassay (STic Expert HIT) for the diagnosis of heparin- induced thrombocytopenia confirmed by the serotonin-release assay: A 30-month,
induced thrombocytopenia. Br J Haematol 166:774, 2014. 16-patient case series. J Thromb Haemost 9:2389, 2011.
83. Davidson SJ, Ortel TL, Smith LJ: Performance of a new, rapid, automated immunoassay 110. Goldfarb MJ, Blostein MD: Fondaparinux in acute heparin-induced thrombocytope-
for the detection of anti-platelet factor 4/heparin complex antibodies. Blood Coagul nia: A case series. J Thromb Haemost 9:2501, 2011.
Fibrinolysis 22:340, 2011. 111. Warkentin TE: Fondaparinux: Does it cause HIT? Can it treat HIT? Expert Rev Hematol
84. Althaus K, Hron G, Strobel U, et al: Evaluation of automated immunoassays in the 3:567, 2010.
diagnosis of heparin induced thrombocytopenia. Thromb Res 131:e85, 2013. 112. Schindewolf M, Steindl J, Beyer-Westendorf J, et al: Frequent off-label use of fondapari-
85. Legnani C, Cini M, Pili C, et al: Evaluation of a new automated panel of assays for nux in patients with suspected acute heparin-induced thrombocytopenia (HIT)–
the detection of anti-PF4/heparin antibodies in patients suspected of having heparin- findings from the GerHIT multi-centre registry study. Thromb Res 134:29, 2014.
induced thrombocytopenia. Thromb Haemost 104:402, 2010. 113. Krauel K, Hackbarth C, Furll B, Greinacher A: Heparin-induced thrombocytopenia: In
86. Van Hoecke F, Devreese K: Evaluation of two new automated chemiluminescent assays vivo studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin,
(HemosIL AcuStar HIT-IgG and HemosIL AcuStar HIT-Ab) for the detection of with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119:1248, 2012.
heparin-induced antibodies in the diagnosis of heparin-induced thrombocytopenia. 114. Anniccherico FJ, Alonso JL: Dabigatran for heparin-induced thrombocytopenia. Mayo
Int J Lab Hematol 34:410, 2012. Clin Proc 88:1036, 2013.
87. Warkentin TE, Sheppard JI, Raschke R, Greinacher A: Performance characteristics of 115. Ng HJ, Than H, Teo EC: First experience with the use of rivaroxaban in the treatment of
a rapid assay for anti-PF4/heparin antibodies: The particle immunofiltration assay. J heparin-induced thrombocytopenia. Thromb Res 135:205, 2015.
Thromb Haemost 5:2308, 2007. 116. Linkins LA, Warkentin TE, Pai M, et al: Design of the rivaroxaban for heparin-induced
88. Andrews DM, Cubillos GF, Paulino SK, et al: Prospective evaluation of the particle thrombocytopenia study. J Thromb Thrombolysis 38:485, 2014.
immunofiltration anti-platelet factor 4 rapid assay in MICU patients with thrombocy- 117. Sachias BS, Rux AH, Cines DB, et al: Rational design and characterization of plate-
topenia. Crit Care 17:R143, 2013. let factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood
89. Sheridan D, Carter C, Kelton JG: A diagnostic test for heparin-induced thrombocy- 119:5955, 2012.
topenia. Blood 67:27, 1986. 118. Reilly MP, Sinha U, André P, et al: PRT-060318, a novel Syk inhibitor, prevents heparin-
90. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C: A rapid and sensitive test for induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood 117:
diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66:734, 1991. 2241, 2011.
91. Price EA, Hayward CP, Moffat KA, et al: Laboratory testing for heparin-induced throm- 119. Stolla M, Stefanini L, André P, et al: CalDAG-GEFI deficiency protects mice in a novel
bocytopenia is inconsistent in North America: A survey of North American specialized model of Fcγ RIIA-mediated thrombosis and thrombocytopenia. Blood 118:1113, 2011.
coagulation laboratories. Thromb Haemost 98:1357, 2007. 120. Cuker A: Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdi-
92. Cuker A, Rux AH, Hinds JL, et al: Novel diagnostic assays for heparin-induced throm- agnosis. Thromb Haemost 106:993, 2011.
bocytopenia. Blood 121:3727, 2013. 121. Smythe MA, Koerber JM, Mehta TP, et al: Assessing the impact of a heparin-induced
93. Nazi I, Arnold DM, Smith JW, et al: FcγRIIa proteolysis as a diagnostic biomarker for thrombocytopenia protocol on patient management, outcomes, and costs. Thromb
heparin-induced thrombocytopenia. J Thromb Haemost 11:1146, 2013. Haemost 108:992, 2012.
94. Greinacher A, Eichler P, Lubenow N, et al: Heparin-induced thrombocytopenia with 122. Watson H, Davidson S, Keeling D; Haemostasis and Thrombosis Task Force of the
thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of British Committee for Standards in Haematology: Guidelines on the diagnosis and
parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96:846, 2000. management of heparin-induced thrombocytopenia: Second edition. Br J Haematol
95. Linkins LA, Dans AL, Moores LK, et al: American College of Chest Physicians: Treat- 159:528, 2012.
ment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy 123. Warkentin TE, Elavathil LJ, Hayward CP, et al: The pathogenesis of venous limb gangrene
and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- associated with heparin-induced thrombocytopenia. Ann Intern Med 127:804, 1997.
Based Clinical Practice Guidelines. Chest 141:e495S, 2012. 124. Sheth SB, DiCicco RA, Hursting MJ, et al: Interpreting the International Normalized Ratio
96. Lewis BE, Wallis DE, Berkowitz SD, et al: ARG-911 Study Investigators: Argatroban (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 85:453, 2001.
anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 125. Hopkins CK, Goldfinger D: Platelet transfusions in heparin-induced thrombocytope-
103:1838, 2001. nia: A report of four cases and review of the literature. Transfusion 48:2128, 2008.
97. Lewis BE, Wallis DE, Leya F, et al: Argatroban-915 Investigators: Argatroban anticoagu- 126. Refaai MA, Chuang C, Menegus M, et al: Outcomes after platelet transfusion in patients
lation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849, with heparin-induced thrombocytopenia. J Thromb Haemost 8:1419, 2010.
2003. 127. Gruel Y, Lang M, Darnige L, et al: Fatal effect of re-exposure to heparin after previous
98. Lewis BE, Wallis DE, Hursting MJ, et al: Effects of argatroban therapy, demographic heparin-associated thrombocytopenia and thrombosis. Lancet 336:1077, 1990.
variables, and platelet count on thrombotic risks in heparin-induced thrombocytope- 128. Pötzsch B, Klövekorn WP, Madlener K: Use of heparin during cardiopulmonary bypass in
nia. Chest 129:1407, 2006. patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343:515, 2000.
99. Walenga JM, Fasanella AR, Iqbal O, Het al: Coagulation laboratory testing in patients 129. Warkentin TE, Sheppard JA: Serological investigation of patients with a previous
treated with argatroban. Semin Thromb Hemost 25:61, 1999. history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood
100. Kiser TH, Fish DN: Evaluation of bivalirudin treatment for heparin-induced thrombo- 123:2485, 2014.
cytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacother- 130. Selleng S, Haneya A, Hirt S, et al: Management of anticoagulation in patients with sub-
apy 26:452, 2006. acute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood
101. Koster A, Dyke CM, Aldea G, et al: Bivalirudin during cardiopulmonary bypass in 112:4024, 2008.
patients with previous or acute heparin-induced thrombocytopenia and heparin anti- 131. Carrier M, Knoll GA, Kovacs MJ, et al: The prevalence of antibodies to the platelet
bodies: Results of the CHOOSE-ON trial. Ann Thorac Surg 83:572, 2007. factor 4–heparin complex and associated with access thrombosis in patients on chronic
102. Skrupky LP, Smith JR, Deal EN, et al: Comparison of bivalirudin and argatroban for the hemodialysis. Thromb Res 120:215, 2007.
management of heparin-induced thrombocytopenia. Pharmacotherapy 30:1229, 2010. 132. Hutchison CA, Dasgupta I: National survey of heparin-induced thrombocytopenia in the
103. Joseph L, Casanegra AI, Dhariwal M, et al: Bivalirudin for the treatment of patients with haemodialysis population of the UK population. Nephrol Dial Transplant 22:1680, 2007.
confirmed or suspected heparin-induced thrombocytopenia. J Thromb Haemost 12:1044, 133. Magnani HN: An analysis of clinical outcomes of 91 pregnancies in 83 women treated
2014. with danaparoid (Orgaran). Thromb Res 125:297, 2010.
104. Boyce SW, Bandyk DF, Bartholomew JR, et al: A randomized, open-label pilot study 134. Hajj-Chahine J, Jayle C, Tomasi J, Corbi P: Successful surgical management of massive
comparing desirudin and argatroban in patients with suspected heparin-induced pulmonary embolism during the second trimester in a parturient with heparin-induced
thrombocytopenia with or without thrombosis: PREVENT-HIT Study. Am J Ther thrombocytopenia. Interact Cardiovasc Thorac Surg 11:679, 2010.
18:14, 2011. 135. Ciurzyński M, Jankowski K, Pietrzak B, et al: Use of fondaparinux in a pregnant woman
105. Chong BH, Gallus AS, Cade JF, et al; Australian HIT Study Group: Prospective randomised with pulmonary embolism and heparin-induced thrombocytopenia. Med Sci Monit
open-label comparison of danaparoid with dextran 70 in the treatment of heparin- 17:CS56, 2011.
induced thrombocytopaenia with thrombosis: A clinical outcome study. Thromb Haemost 136. Dempfle CE: Minor transplacental passage of fondaparinux in vivo. N Engl J Med
86:1170, 2001. 350:1914, 2004.

Kaushansky_chapter 118_p2025-2034.indd 2034 9/18/15 5:43 PM